Get started
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

MANKIND chart


Full chart

MANKIND upcoming earnings


Next report date
≈
May 14
Report period
Q4 2024
EPS estimate
13.30 INR
Revenue estimate
‪32.73 B‬ INR

Key stats


Market capitalization
‪996.81 B‬ INR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
44.15
Basic EPS (TTM)
50.90 INR
Net income (FY)
‪19.13 B‬ INR
Revenue (FY)
‪103.34 B‬ INR
Shares float
‪104.43 M‬
Beta (1Y)
0.46

Employees


Employees (FY)
‪19.54 K‬
Change (1Y)
‪+1.07 K‬ +5.80%
Revenue / Employee (1Y)
‪5.29 M‬ INR
Net income / Employee (1Y)
‪978.96 K‬ INR

About MANKIND PHARMA LTD


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Sheetal Arora
Website
mankindpharma.com
Headquarters
New Delhi
Founded
1986
ISIN
INE634S01028
FIGI
BBG01G9WXGC8
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.

Financials


Performance
‪10%‬
‪13%‬
‪16%‬
‪19%‬
‪22%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:May 14, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪4.50‬
‪9.00‬
‪13.50‬
‪18.00‬
Actual
Estimate

MANKIND news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

MANKIND highest yielding bonds


797MPL27
MPL-7.97%-16-11-27-PVT
Yield to maturity
—
Maturity date
Nov 16, 2027
799MPL26A
MPL-7.99%-16-10-26-PVT
Yield to maturity
—
Maturity date
Oct 16, 2026
799MPL26
MPL-7.99%-16-4-26-PVT
Yield to maturity
—
Maturity date
Apr 16, 2026

See all MANKIND bonds 

Frequently Asked Questions


The current price of MANKIND is 2,415.05 INR — it has increased by 7.58% in the past 24 hours. Watch MANKIND PHARMA LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange MANKIND PHARMA LTD stocks are traded under the ticker MANKIND.
MANKIND stock has risen by 10.27% compared to the previous week, the month change is a 1.30% rise, over the last year MANKIND PHARMA LTD has showed a 12.33% increase.
We've gathered analysts' opinions on MANKIND PHARMA LTD future price: according to them, MANKIND price has a max estimate of 3,300.00 INR and a min estimate of 2,150.00 INR. Watch MANKIND chart and read a more detailed MANKIND PHARMA LTD stock forecast: see what analysts think of MANKIND PHARMA LTD and suggest that you do with its stocks.
MANKIND reached its all-time high on Dec 23, 2024 with the price of 3,054.80 INR, and its all-time low was 1,242.00 INR and was reached on May 22, 2023. View more price dynamics on MANKIND chart.
See other stocks reaching their highest and lowest prices.
MANKIND stock is 9.11% volatile and has beta coefficient of 0.46. Track MANKIND PHARMA LTD stock price on the chart and check out the list of the most volatile stocks — is MANKIND PHARMA LTD there?
Today MANKIND PHARMA LTD has the market capitalization of ‪996.81 B‬, it has decreased by −1.73% over the last week.
Yes, you can track MANKIND PHARMA LTD financials in yearly and quarterly reports right on TradingView.
MANKIND PHARMA LTD is going to release the next earnings report on May 14, 2025. Keep track of upcoming events with our Earnings Calendar.
MANKIND earnings for the last quarter are 9.60 INR per share, whereas the estimation was 11.36 INR resulting in a −15.51% surprise. The estimated earnings for the next quarter are 13.30 INR per share. See more details about MANKIND PHARMA LTD earnings.
MANKIND PHARMA LTD revenue for the last quarter amounts to ‪32.30 B‬ INR, despite the estimated figure of ‪32.06 B‬ INR. In the next quarter, revenue is expected to reach ‪32.73 B‬ INR.
MANKIND net income for the last quarter is ‪3.80 B‬ INR, while the quarter before that showed ‪6.53 B‬ INR of net income which accounts for −41.81% change. Track more MANKIND PHARMA LTD financial stats to get the full picture.
No, MANKIND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 23, 2025, the company has ‪19.54 K‬ employees. See our rating of the largest employees — is MANKIND PHARMA LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MANKIND PHARMA LTD EBITDA is ‪29.53 B‬ INR, and current EBITDA margin is 24.98%. See more stats in MANKIND PHARMA LTD financial statements.
Like other stocks, MANKIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MANKIND PHARMA LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MANKIND PHARMA LTD technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MANKIND PHARMA LTD stock shows the buy signal. See more of MANKIND PHARMA LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.